{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin+%28XIFAXAN%29",
    "query": {
      "intervention": "Rifaximin (XIFAXAN)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 79,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin+%28XIFAXAN%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T21:34:24.239Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07209371",
      "title": "Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Monoclonal Gammopathy of Undetermined Significance",
        "Non-IgM Monoclonal Gammopathy of Undetermined Significance"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-01-22",
      "completion_date": "2028-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-09-29T21:34:24.239Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07209371"
    },
    {
      "nct_id": "NCT03712280",
      "title": "MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatic Cirrhosis",
        "Hepatic Encephalopathy (HE)"
      ],
      "interventions": [
        {
          "name": "MNK6106",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2018-12-01",
      "completion_date": "2020-07-14",
      "has_results": true,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-09-29T21:34:24.239Z",
      "location_count": 4,
      "location_summary": "Coronado, California • Rialto, California • St. Petersburg, Florida + 1 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03712280"
    },
    {
      "nct_id": "NCT01904409",
      "title": "Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 40 mg IR tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 80 mg IR tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 40 mg SER tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 80 mg SER tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 80mgIR/80mgSER tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2013-06",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2019-10-23",
      "last_synced_at": "2026-09-29T21:34:24.239Z",
      "location_count": 113,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01904409"
    },
    {
      "nct_id": "NCT05098028",
      "title": "Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Low Dose Rifaximin ER",
          "type": "DRUG"
        },
        {
          "name": "Low Dose Rifaximin DER",
          "type": "DRUG"
        },
        {
          "name": "High Dose Rifaximin ER",
          "type": "DRUG"
        },
        {
          "name": "High Dose Rifaximin DER",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 44,
      "start_date": "2022-03-22",
      "completion_date": "2023-09-04",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-29T21:34:24.239Z",
      "location_count": 5,
      "location_summary": "Orange, California • Denver, Colorado • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05098028"
    },
    {
      "nct_id": "NCT03515044",
      "title": "Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overt Hepatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "40 mg Rifaximin SSD once daily",
          "type": "DRUG"
        },
        {
          "name": "40 mg Rifaximin SSD twice daily",
          "type": "DRUG"
        },
        {
          "name": "80 mg Rifaximin SSD once daily",
          "type": "DRUG"
        },
        {
          "name": "80 mg Rifaximin SSD twice daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 71,
      "start_date": "2018-09-13",
      "completion_date": "2020-03-12",
      "has_results": true,
      "last_update_posted_date": "2023-04-13",
      "last_synced_at": "2026-09-29T21:34:24.239Z",
      "location_count": 34,
      "location_summary": "Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more",
      "locations": [
        {
          "city": "Corona del Mar",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bristol",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03515044"
    },
    {
      "nct_id": "NCT02280044",
      "title": "Efficacy of Rifaximin in Preventing Campylobacteriosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Dysentery",
        "Diarrhea",
        "Enteric Campylobacteriosis"
      ],
      "interventions": [
        {
          "name": "Rifaximin intervention",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo intervention",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Johns Hopkins Bloomberg School of Public Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-10",
      "completion_date": "2016-08-09",
      "has_results": true,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-09-29T21:34:24.239Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02280044"
    },
    {
      "nct_id": "NCT02470780",
      "title": "Treating Bacterial Overgrowth in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Small Intestinal Bacterial Overgrowth"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2015-12",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-09-29T21:34:24.239Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02470780"
    },
    {
      "nct_id": "NCT02498418",
      "title": "Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Xifaxan®",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 739,
      "start_date": "2016-01-06",
      "completion_date": "2017-02-28",
      "has_results": true,
      "last_update_posted_date": "2019-12-05",
      "last_synced_at": "2026-09-29T21:34:24.239Z",
      "location_count": 1,
      "location_summary": "Coral Gables, Florida",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02498418"
    },
    {
      "nct_id": "NCT01842113",
      "title": "Quality of Life and Nutritional Improvements in Cirrhotic Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Liver Cirrhosis",
        "Hepatic Encephalopathy",
        "Portal Hypertension"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Lactulose",
          "type": "DRUG"
        },
        {
          "name": "Lactulose Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tampa General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2013-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-23",
      "last_synced_at": "2026-09-29T21:34:24.239Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01842113"
    },
    {
      "nct_id": "NCT01069133",
      "title": "Study of Rifaximin in Minimal Hepatic Encephalopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Minimal Hepatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hunter Holmes Mcguire Veteran Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-02",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2012-12-11",
      "last_synced_at": "2026-09-29T21:34:24.239Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01069133"
    }
  ]
}